U.S. markets closed

Aptevo Therapeutics Inc. (APVO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
27.36-0.92 (-3.25%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Head and Shoulders Bottom

Head and Shoulders Bottom

Previous Close28.28
Open28.44
Bid27.40 x 1000
Ask27.99 x 1000
Day's Range26.01 - 29.28
52 Week Range5.67 - 60.00
Volume156,516
Avg. Volume56,607
Market Cap121.739M
Beta (5Y Monthly)7.14
PE Ratio (TTM)N/A
EPS (TTM)-7.59
Earnings DateNov 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est61.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • ACCESSWIRE

    Aptevo Therapeutics Announces Expansion Phase of Lead Anti-Leukemia Drug APVO436 in Adult Patients with Acute Myeloid Leukemia

    Initiates Multi-Center, Multi-Arm Trial Using Active Dose Identified in the Dose Escalation Phase of the TrialSEATTLE, WA / ACCESSWIRE / May 27, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIRTM and ADAPTIR-FLEXTM platform technologies today announced that the company has initiated the expansion phase of lead anti-leukemia drug candidate, APVO436, in adult patients with acute myeloid leukemia (AML) with a multi-center, multi-arm trial using the active recommended dose identified in the dose escalation phase (Part 1) of the study.

  • Aptevo Stock Gains on Encouraging Single-Agent Activity for APVO436 In Leukemia Patients
    Benzinga

    Aptevo Stock Gains on Encouraging Single-Agent Activity for APVO436 In Leukemia Patients

    Aptevo Therapeutics Inc (NASDAQ: APVO) has announced positive results from Phase 1 dose-escalation trial evaluating lead ADAPTIR candidate, APVO436, for acute myeloid leukemia and myelodysplastic syndromes (AML/MDS). The study met its primary endpoint of identification of an active dose level for advanced studies. The Company plans to submit the data for publication later this year. Of seven evaluable relapsed AML patients treated in Cohort 6, four showed stabilization of their leukemias. Of those four patients with disease stabilization, three patients lived over 246 days, over 261 days, and over 281 days, respectively, and one progressed after a month. Two relapsed AML patients, who experienced stabilization of their leukemia, achieved partial remission and subsequently a complete remission. No partial or complete remissions have been observed at APVO436 dose levels either lower or higher than the Cohort 6 dose level. APVO436 was generally well tolerated and demonstrated a favorable side effect profile, including the absence of severe or prolonged neutropenia, an often serious condition associated with CD123-targeting therapies. Price Action: APVO shares are up 9.7% at $27.71 during the market session on the last check Wednesday. See more from BenzingaClick here for options trades from BenzingaVistaGen Kick Starts Late-Stage Social Anxiety Disorder Study with PH94BDyadic's Stock Jumps On COVID-19 Vaccine Development Pact In India© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • ACCESSWIRE

    Aptevo Therapeutics Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults With Relapsed Acute Myeloid Leukemia

    * Dose Escalation Study of APVO436 Shows Favorable Safety Profile and No Severe Neutropenia, a Potentially Life-threatening Side Effect, Reported in a Significant Number of Patients Receiving CD123-Targeting Drugs * Dosing Level Established For Advanced Clinical TrialsSEATTLE, WA / ACCESSWIRE / May 26, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced positive results from the Company's Phase 1 dose escalation trial evaluating lead ADAPTIR candidate, APVO436, for the treatment of acute myeloid leukemia and myelodysplastic syndromes (AML/MDS).